Three opioid antagonists, naloxone, naltrexone, and nalmefene, are currently approved for human use. Naloxone and nalmefene have been approved for parenteral administration and are used in the ...

来自某医疗机构的研究人员针对酒精相关性肝病(ALD)患者难以实现完全戒酒的问题，开展了一项关于阿片受体调节剂纳美芬(nalmefene)的回顾性研究。结果显示，该药物能显著减少重度饮酒天数，改善肝功能指标，且安全性良好，为ALD患者的减害策略提供了新选择。

Preliminary results from a Phase III clinical trial of nalmefene in individuals with alcohol addiction have shown that this opioid receptor antagonist reduces alcohol consumption. If this drug is ...

The results, published in the Journal of Clinical Pharmacology, support the nalmefene auto-injector as an important treatment option to support emergency opioid overdose reversal STAMFORD, Conn., ...

Credit: Shutterstock. Nalmefene HCl is an alternative to naloxone to reverse the effects of opioids, including respiratory depression, sedation, and hypotension. The Food and Drug Administration (FDA) ...

Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone. Nalmefene Hydrochloride Injection is now available for the complete or partial reversal of opioid drug ...

STAMFORD, Conn., October 28, 2024--(BUSINESS WIRE)--Purdue Pharma L.P. ("Purdue") today announced The Journal of Clinical Pharmacology has published findings from a study in healthy adult volunteers ...

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma has completed the first phase of a study examining the use of nalmefene hydrochloride (HCI) injection in real-world emergency department (ED) settings.

Nalmefene has a significant potential for helping individuals with alcohol dependence in reducing their alcohol consumption and allowing individuals to be in control of their alcohol intake The ...

Purdue Pharma has obtained the Food and Drug Administration’s clearance for nalmefene hydrochloride injection, 2mg/2mL (1mg/1mL). Nalmefene is an opioid antagonist indicated for the complete or ...

The FDA approved the first nalmefene hydrochloride auto-injector (Zurnai) for use as an emergency treatment for opioid overdose in adults and children 12 years of age and older, the agency announced ...

Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The "Nalmefene (CAS 55096-26-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...